Biomarkers for the diagnosis and treatment of stroke

By detecting biomarkers such as DAAM2, ECHDC3, FOLR3, etc., and using a variety of technical means, the problem of early diagnosis of stroke is solved, the diagnostic accuracy and the implementation of treatment measures are improved, and the disability rate is reduced.

CN114250294BActive Publication Date: 2024-11-26TAIYUAN PSYCHIATRIC HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111587626.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-12-23
Publication Date
2024-11-26
Estimated Expiration
2041-12-23

AI Technical Summary

Technical Problem

The early diagnosis rate of stroke is not ideal, the existing magnetic resonance imaging technology is low in popularity and costly in China, which makes it difficult to implement treatment measures and lacks sensitive and specific biomarkers for stroke diagnosis.

Method used

Provide a product, including reagents that detect the expression levels of biomarkers such as DAAM2, ECHDC3, FOLR3 in samples, and use digital imaging technology, protein immunity technology and other methods to diagnose ischemic and hemorrhagic strokes, and provide corresponding Pharmaceutical compositions and systems or devices for the prevention or treatment of stroke.

Benefits of technology

By detecting the level of biomarkers, the diagnostic accuracy and predicting risks of stroke are improved, new diagnostic pathways are provided, the basis for implementing stroke treatment measures is enhanced, and the disability rate is reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114250294B_ABST
    Figure CN114250294B_ABST
Patent Text Reader

Abstract

The present invention relates to markers that can be used for diagnosing and treating stroke, and the markers include two or three of DAAM2, ECHDC3, and FOLR3. Compared with a normal control group, the expression levels of the above three markers are significantly increased in stroke patients. The present invention provides a pharmaceutical composition that can be used to treat stroke. The present invention also provides a system or device for diagnosing whether a subject suffers from stroke or predicting whether a subject has a risk of suffering from stroke. The markers involved in the present invention have high sensitivity, good specificity, and good application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to markers that can be used for diagnosing and treating stroke. Background Art

[0002] Stroke is a sudden onset of cerebral blood circulation disorder and one of the major diseases that endanger human health. Stroke has become the leading cause of disability and the third cause of death worldwide, and two-thirds of the deaths caused by it are concentrated in developing countries. Stroke includes ischemic stroke and hemorrhagic stroke. Studies have shown that the incidence of ischemic stroke in the Chinese population is greater than that of hemorrhagic stroke. Clinical investigations and studies have shown that the incidence of stroke is still on the rise, and it has the characteristics of high mortality, high incidence, and high disability. In mild cases, it affects the quality of life of patients, and in severe cases, it leads to paralysis, aphasia, dementia and even death. Stroke not only seriously affects the quality of life of patients, but also brings a heavy burden to families and society. Although magnetic resonance imaging (MIR) has important reference value in the diagnosis of stroke, the early diagnosis rate of stroke is still not ideal due to the low penetration rate and high cost of MIR in China. Timely and accurate diagnosis is an important basis for the implementation of treatment measures, thereby reducing the disability rate of stroke.

[0003] Due to the development of proteomics and genomics, the research and development of disease-related biomarkers has developed rapidly. Biomarkers provide a very important basis for the rapid diagnosis, treatment guidance and prognosis assessment of diseases in other systems other than brain tissue. For decades, many researchers have been committed to exploring the relationship between biomarkers and stroke. Finding sensitive and specific biomarkers is expected to provide a new way for stroke diagnosis. Summary of the invention

[0004] The first object of the present invention is to provide a product that can be used for diagnosing stroke.

[0005] The second object of the present invention is to provide a pharmaceutical composition for preventing or treating stroke.

[0006] The third object of the present invention is to provide a system or device for diagnosing whether a subject has suffered from a stroke or predicting whether a subject has a risk of suffering from a stroke.

[0007] To achieve the above object, the present invention adopts the following technical solutions:

[0008] In one aspect, the present invention provides a product that can be used to diagnose stroke, wherein the product comprises a reagent that can detect the expression level of biomarkers in a sample, and the biomarkers comprise two or three of DAAM2, ECHDC3, and FOLR3.

[0009] Furthermore, the stroke includes ischemic stroke and hemorrhagic stroke.

[0010] Furthermore, the stroke is ischemic stroke.

[0011] Furthermore, the ischemic stroke includes large artery atherosclerotic stroke, cardiogenic cerebral embolism, small artery occlusive stroke, or ischemic stroke caused by other reasons.

[0012] Furthermore, the ischemic stroke is cardiogenic cerebral embolism.

[0013] Furthermore, the reagents include reagents for detecting the expression level of biomarkers in samples through digital imaging technology, protein immunoassay technology, dye technology, nucleic acid sequencing technology, nucleic acid hybridization technology, chromatography technology, and mass spectrometry technology.

[0014] Furthermore, the sample is blood.

[0015] Furthermore, the reagents include primers or probes that specifically bind to the biomarker gene; antibodies, peptides, aptamers or compounds that specifically bind to the marker protein.

[0016] Furthermore, the products include nucleic acid membrane strips, preparations, chips, and test kits.

[0017] Another aspect of the present invention provides the use of biomarkers in the preparation of the aforementioned product, wherein the biomarkers include two or three of DAAM2, ECHDC3, and FOLR3.

[0018] Another aspect of the present invention provides a pharmaceutical composition, which comprises two or three of a DAAM2 inhibitor, an ECHDC3 inhibitor, and a FOLR3 inhibitor.

[0019] Another aspect of the present invention provides use of the aforementioned pharmaceutical composition in the preparation of a drug for preventing or treating stroke.

[0020] Furthermore, the stroke includes ischemic stroke and hemorrhagic stroke.

[0021] Furthermore, the stroke is ischemic stroke.

[0022] Furthermore, the ischemic stroke includes large artery atherosclerotic stroke, cardiogenic cerebral embolism, small artery occlusive stroke, or ischemic stroke caused by other reasons.

[0023] Furthermore, the ischemic stroke is cardiogenic cerebral embolism.

[0024] Another aspect of the present invention provides a system or device for diagnosing whether a subject suffers from a stroke or predicting whether a subject has a risk of suffering from a stroke, the system / device comprising:

[0025] an analysis unit adapted to measure the amount of a biomarker in a sample from a subject; and

[0026] an evaluation unit comprising a stored reference and a data processor having implemented therein an algorithm for comparing the amount of the biomarker measured by the analysis unit with the stored reference, thereby diagnosing whether the subject suffers from a stroke or predicting whether the subject is at risk of suffering from a stroke;

[0027] The biomarkers include two or three of DAAM2, ECHDC3, and FOLR3;

[0028] Furthermore, the stroke includes ischemic stroke and hemorrhagic stroke.

[0029] Furthermore, the stroke is ischemic stroke.

[0030] Furthermore, the ischemic stroke includes large artery atherosclerotic stroke, cardiogenic cerebral embolism, small artery occlusive stroke, or ischemic stroke caused by other reasons.

[0031] Furthermore, the ischemic stroke is cardiogenic cerebral embolism.

[0032] The present invention also provides a computer-readable storage medium having a computer program stored thereon, wherein the computer program implements the above-mentioned system / device when executed by a processor. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 is the box plot of differential expression of DAAM2;

[0034] Figure 2 is the box plot of differential expression of ECHDC3;

[0035] Figure 3 is the box plot of differential expression of FOLR3;

[0036] Figure 4 ROC curve for DAAM2 in diagnosing cardiogenic cerebral embolism;

[0037] Figure 5 ROC curve for ECHDC3 in diagnosing cardiogenic cerebral embolism;

[0038] Figure 6 ROC curve of FOLR3 in diagnosing cardiogenic cerebral embolism;

[0039] Figure 7 The ROC curve of DAAM2 and ECHDC3 combined in the diagnosis of cardiogenic cerebral embolism;

[0040] Figure 8 The ROC curve of ECHDC3 and FOLR3 combined in the diagnosis of cardiogenic cerebral embolism;

[0041] Fig. 9 The ROC curve of DAAM2 and FOLR3 combined in the diagnosis of cardiogenic cerebral embolism;

[0042] Fig.10 This is the ROC curve of DAAM2+ECHDC3+FOLR3 combined diagnosis of cardiogenic cerebral embolism. DETAILED DESCRIPTION

[0043] Biomarkers

[0044] The present invention provides a product that can be used for diagnosing stroke. The product comprises a reagent that can detect biomarkers. The biomarkers comprise two or three of DAAM2, ECHDC3, and FOLR3.

[0045] The term "biomarker" refers to a biological molecule present in an individual at varying concentrations that can be used to predict a disease state in the individual. Biomarkers may include, but are not limited to, nucleic acids, proteins, and variants and fragments thereof. A biomarker may be a DNA comprising all or part of a nucleic acid sequence encoding the biomarker or the complement of such a sequence. Biomarker nucleic acids useful in the present invention are contemplated to include DNA and RNA comprising all or part of any nucleic acid sequence of interest.

[0046] The DAAM2 mentioned above refers to the gene with Gene ID 23500.

[0047] The ECHDC3 mentioned above refers to the gene with Gene ID 79746.

[0048] The FOLR3 mentioned above refers to the gene with Gene ID 2352.

[0049] The term "primer" or "probe" encompasses oligonucleotides with a specific sequence or oligonucleotides with a specific sequence. In other embodiments, nucleic acids are detected by indirect detection methods. For example, biotinylated probes can be combined with streptavidin-conjugated dyes to detect bound nucleic acids. The streptavidin molecule binds to the biotin label on the amplified biomarker, and the bound biomarker is detected by detecting the dye molecule attached to the streptavidin molecule. In one embodiment, the dye molecule conjugated to streptavidin comprises PHYCOLINK. Streptavidin R-phycoerythrin (PROzyme). Other conjugated dye molecules are known to those skilled in the art.

[0050] Labels include, but are not limited to: luminescent, light scattering and light absorbing compounds that produce or quench detectable fluorescent, chemiluminescent or bioluminescent signals. In some embodiments, dual-labeled fluorescent probes including reporter fluorophores and quencher fluorophores are used. It should be understood that pairs of fluorophores with different emission spectra are selected so that they can be easily distinguished. In certain embodiments, the label is a hybridization stabilizing portion that is used to enhance, stabilize or affect the hybridization of the duplex, for example, intercalators and intercalating dyes.

[0051] The term "antibody" refers to an immunoglobulin that specifically recognizes an epitope on a target antigen, the recognition being determined by the binding properties of the immunoglobulin variable regions of the heavy and light chains (VHS and VLS), more specifically, by the binding properties of the complementary determining regions (CDRs). Many potential antibody formats are known in the art and may include, but are not limited to: multiple intact monoclonal antibodies or polyclonal mixtures containing intact monoclonal antibodies, antibody fragments (such as Fab, Fab' and Fv fragments, multispecific antibodies containing antibody fragments and linear single-chain antibodies), single-chain variable fragments (scFvS), multispecific antibodies, chimeric antibodies, humanized antibodies and fusion proteins, which contain the domains necessary to recognize a given epitope on a target antigen. Preferably, the antibodies cited in the context of the present invention refer to monoclonal antibodies. Antibodies can also be coupled to various detectable labels to enable detection, including but not limited to radionuclides, fluorescent probes, dyes or enzymes, such as horseradish peroxidase and alkaline phosphatase.

[0052] The term "aptamer" refers to an oligonucleotide molecule or a polypeptide molecule that can specifically bind to a target molecule. Oligonucleotide aptamers can be nucleotides (RNA) or deoxynucleotides (DNA) and are usually composed of short oligonucleotide chains. Polypeptide aptamers are usually composed of short peptide domains that can be attached to one or both ends of a protein backbone.

[0053] The term "specific binding", in the context of antibody-epitope interactions, refers to an interaction in which the antibody and epitope bind more frequently or more quickly, or for a longer period of time or with greater affinity, or in a combination of any of the above, than when either the antibody or the epitope is replaced by a substitute, such as an unrelated protein. Typically, but not necessarily, the binding referred to refers to specific recognition. In addition, it should be understood that an antibody can specifically recognize more than one antigen. Techniques known in the art for determining specific binding or lack thereof to a target by monoclonal antibodies include, but are not limited to, FACS analysis, immunocytochemical staining, immunohistochemistry, Western blotting / dot blotting, ELISA, and affinity chromatography. As an example and not limitation, specific binding or lack thereof can be determined by comparative analysis with controls, the controls comprising antibodies known in the art that can specifically recognize the target, and / or controls that do not specifically recognize or minimally specifically recognize the target (e.g., the controls comprise the use of nonspecific antibodies). The comparative analysis can be qualitative or quantitative. However, it should be understood that an antibody or binding portion that specifically recognizes a given target exclusively is reported to have a higher specificity for that target than an antibody, such as an antibody that specifically recognizes both the given target and a homologous protein.

[0054] Reagent test kit

[0055] The present invention provides a kit for diagnosing stroke, which is used to determine the level of biomarkers (wherein the sequence optionally contains uracil to replace one, more than one or all of the disclosed thymines) and combinations thereof. The kit may include materials and reagents suitable for selectively detecting the presence of biomarkers or biomarker groups for diagnosing stroke in samples derived from subjects. For example, in one embodiment, the kit may include reagents that specifically hybridize with biomarkers. Such reagents can be nucleic acid molecules in a form suitable for detecting biomarkers, such as probes or primers. The kit may include reagents for performing assays to detect one or more biomarkers, for example, reagents that can be used to detect one or more biomarkers in a qPCR reaction. The kit may also include a microarray for detecting one or more biomarkers.

[0056] In further embodiments, the kit may contain instructions for appropriate operating parameters in the form of a label or product insert. For example, the instructions may include information or guidance on how to collect a sample, how to determine the level of one or more biomarkers in a sample, or how to correlate the level of one or more biomarkers in a sample with the stroke status of a subject.

[0057] In another embodiment, a kit can contain one or more containers with a biomarker sample for use as a reference standard, a suitable control, or calibration for an assay to detect the biomarker in a test sample.

[0058] Pharmaceutical composition

[0059] The present invention provides a pharmaceutical composition, which comprises two or three of a DAAM2 inhibitor, an ECHDC3 inhibitor, and a FOLR3 inhibitor.

[0060] The inhibitor comprises nucleic acid molecules, carbohydrates, small molecule compounds or interfering lentiviruses; the nucleic acid molecules are selected from: antisense oligonucleotides, double-stranded RNA, small interfering RNA or short hairpin RNA.

[0061] As used herein, the "small interfering RNA" is a double-stranded small RNA molecule, which consists of a completely complementary first strand and a second strand, and is processed by Dicer (an enzyme in the RNAaseⅢ family that is specific for double-stranded RNA). The first strand and the second strand complement each other to form an RNA dimer, and the sequence of the first strand is the same as the target sequence in the biomarker gene described above, or is a sequence that hybridizes with the target sequence under high stringency conditions. The length of the first and second strands of the double-stranded RNA is 15-27 nucleotides; preferably, the length is 19-23 nucleotides; more preferably, the length is 19, 20 or 21 nucleotides. siRNA is a major member of siRISC, which stimulates the silencing of target genes complementary to it. RNA interference (RNAi) refers to the specific degradation of intracellular mRNA mediated by endogenous or exogenous double-stranded RNA (dsRNA), which leads to the silencing of the expression of the target gene and the corresponding loss of functional phenotype.

[0062] As used herein, the shRNA, i.e., a small hairpin RNA or short hairpin RNA (shRNA), is an RNA sequence with a tight hairpin turn, which comprises a sense strand segment, an antisense strand segment, and a stem-loop structure connecting the sense strand segment and the antisense strand segment, and is often used for RNA interference to silence the expression of a target gene. The sequences of the sense strand and the antisense strand are complementary, and the sequence of the sense strand segment is identical to 15-27 consecutive nucleotide sequences in the aforementioned biomarker gene, preferably, the sense strand segment is identical to 19-23 consecutive nucleotide sequences in the aforementioned biomarker gene; more preferably, the sense strand segment is identical to 19, 20 or 21 consecutive nucleotide sequences in the aforementioned biomarker gene, or is a sequence that hybridizes with the above sequences under high stringency conditions. The hairpin structure of shRNA can be cleaved into siRNA by the cellular machinery, and then siRNA binds to the RNA-induced silencing complex (RISC), which can bind to the target gene and degrade it.

[0063] The small interfering RNA described in the present invention can be a chemically synthesized double-stranded RNA; it can also be a double-stranded RNA expressed by a vector or an expression framework, in which, for example, an RNA polymerase III promoter and an RNA polymerase III terminator can be used to regulate the expression of the small interfering RNA in mammalian cells, and the RNA polymerase III promoter includes a human or mouse U6 promoter and a human H1 promoter, etc.

[0064] The small interfering RNA described in the present invention may be composed of a single small interfering RNA acting on one target sequence, or may be composed of multiple small interfering RNAs acting on multiple target sequences of one gene or target sequences on multiple genes; the target sequence may be the genomic sequence of the biomarker gene described above, or the cDNA sequence of the biomarker gene described above.

[0065] The siRNA of the present invention can be screened by the methods disclosed in the Examples herein or by methods known in the art.

[0066] The sequences of the first strand in the siRNA of the present invention and the sense strand in the shRNA are identical to the target sequence, and have at least 10 consecutive (preferably at least 15 consecutive, more preferably at least 18 consecutive) identical nucleotide sequences with the siRNA target sequence, or are sequences that hybridize with the target sequence under highly stringent conditions.

[0067] In the present invention, the nucleic acid construct refers to a sequence including a replication system and being able to be transcribed in a given target cell. It can be obtained by cloning a fragment encoding the shRNA described herein into a known vector. Further, the nucleic acid construct is a lentiviral vector. After the lentiviral vector is packaged into infectious viral particles, it infects cells and then transcribes the shRNA described in the present invention. After enzyme processing and other steps, the siRNA is finally obtained for specific silencing of the expression of the biomarker gene described above.

[0068] The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier. The term carrier includes any and all solvents, diluents or other liquid vehicles, dispersing or suspending aids, surfactants, isotonic agents, thickeners or emulsifiers, preservatives, solid binders, lubricants, etc. suitable for preparing the desired specific dosage form. Some examples of materials that can be used as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol and phosphate buffers, and other nontoxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as colorants, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants may also be present in the composition, according to the judgment of the formulator.

[0069] When preparing the pharmaceutical composition of the present invention, active ingredient is usually mixed with excipient, or diluted with excipient, or wrapped in a carrier that can exist in the form of capsule or sachet. When excipient acts as a diluent, it can be a solid, semisolid or liquid material as a medium for excipient, carrier or active ingredient. Therefore, the composition can be a tablet, a pill, a powder, a solution, a syrup, a sterile injection solution, etc. The example of suitable excipient includes: lactose, glucose, sucrose, sorbitol, mannitol, starch, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, etc. The preparation can also include: a wetting agent, an emulsifier, a preservative (such as methyl hydroxybenzoate and propyl ester), a sweetener, etc.

[0070] The application of the pharmaceutical composition provides a method for treating cerebral stroke, specifically a method for preventing or treating cerebral stroke in a subject, comprising administering an effective dose of the pharmaceutical composition to the subject.

[0071] When the pharmaceutical composition is used to prevent or treat a stroke in a subject, it is necessary to apply the pharmaceutical composition of an effective dose to the subject. Typical dosage forms for topical administration include creams, ointments, sprays, lotions and plasters. However, the pharmaceutical composition can be formulated for any type of administration, for example, utilizing intradermal injection, subcutaneous injection, intravenous injection, intramuscular injection, intranasal injection, intracerebral injection, intratracheal injection, intraarterial injection, intraperitoneal injection, intravesical injection, intrapleural injection, intracoronary artery or intratumoral injection of a syringe or other device. It is also contemplated that the dosage form is administered by inhalation (for example, aerosol) or oral administration, rectal administration or vaginal administration.

[0072] System or device

[0073] The present invention relates to a system / device for diagnosing whether a subject suffers from a stroke or predicting whether a subject has a risk of suffering from a stroke, comprising:

[0074] an analysis unit adapted to measure the amount of a biomarker in a sample from a subject; and

[0075] An evaluation unit comprising a stored reference and a data processor having implemented an algorithm for comparing the amount of the biomarker measured by the analysis unit with the stored reference, thereby diagnosing whether the subject has suffered a stroke or predicting whether the subject is at risk of suffering a stroke.

[0076] The device as used herein should include at least the above-mentioned units. The units of the device are operably connected to each other. How to link the units in an operational manner will depend on the type of units included in the device. For example, in the case of applying an instrument for automatic quantitative measurement of biomarkers in an analysis unit, the data obtained by the automatic operation unit can be processed by an evaluation unit, for example, by a computer program running on a computer as a data processor, so as to facilitate diagnosis. In one embodiment, a data processor implements a comparison of the amount of a biomarker with a reference.

[0077] Further, in this case, the unit is composed of a single device. However, the analysis unit and the evaluation unit may also be physically separated. In this case, an operative linkage may be achieved via a wired and wireless connection between the units that allow data transmission. The wireless connection may use a wireless LAN (WLAN) or the Internet. A wired connection may be achieved by optical and non-optical cable connections between the units. The cable for a wired connection is further suitable for high-throughput data transmission.

[0078] The specific implementation of the present application is described in detail below in conjunction with the accompanying drawings. It should be understood that the specific implementation described here is only used to illustrate and explain the present application, and is not used to limit the present application.

[0079] Example 1 High-throughput sequencing analysis

[0080] 1. Sample collection

[0081] Blood samples were collected from 4 stroke patients and 4 healthy controls.

[0082] 1.1 Inclusion criteria for stroke patients:

[0083] (1) Diagnosis of stroke;

[0084] (2) Have not received any treatment for stroke, such as medication or surgery;

[0085] (3) No infectious, autoimmune or serious chronic diseases.

[0086] 1.2 Inclusion criteria for healthy controls:

[0087] (1) Male or female volunteers, aged between 20 and 90 years old;

[0088] (2) Being in good health and without any chronic, infectious or genetic diseases;

[0089] (3) no recent use of regular prescription medications;

[0090] (4) not donated blood, was not pregnant, and had not received any vaccination within 3 months before the start of the study;

[0091] (5) Non-allergic constitution;

[0092] (6) Good health confirmed through routine physical examination.

[0093] 2. Experimental methods

[0094] 2.1 Extraction of total RNA from blood

[0095] Total RNA was extracted from peripheral blood using the PAXgene Blood RNA Kit.

[0096] 2.2 Sample testing

[0097] Agilent 2100 Bioanalyzer (Agilent RNA 6000 Nano Kit) was used to detect the total RNA concentration, RIN value, 28S / 18S and fragment size.

[0098] 2.3 Library construction and transcriptome sequencing

[0099] 1) DNase digestion to remove DNA: Use DNase I to digest the DNA fragments in the Total RNA sample, purify the reaction products with magnetic beads, and finally dissolve them in DEPC water.

[0100] 2) Removal of rRNA: Remove the purified Total RNA sample and use a kit to remove rRNA. After removal, perform Agilent 2100 detection to verify the rRNA removal effect.

[0101] 3) RNA shearing: Take the sample from the previous step, add shearing buffer, and place it in a PCR instrument for thermal shearing to 130-160 nt;

[0102] 4) Synthesis of one strand of reverse transcription: add an appropriate amount of primers to the sheared sample, mix thoroughly, and react in a Thermomixer at an appropriate temperature for a certain period of time to open the secondary structure and bind to the primers, then add the one-strand synthesis reaction system Mix prepared in advance, and synthesize one strand of cDNA according to the corresponding program on the PCR instrument;

[0103] 5) Synthesis of reverse transcription second strand: prepare the second strand synthesis reaction system, react at an appropriate temperature for a certain period of time on the Thermomixer to synthesize the second strand cDNA, and purify and recover the reaction product with magnetic beads. The product is purified and recovered with magnetic beads;

[0104] 6) End repair: Prepare the end repair reaction system, react at an appropriate temperature for a certain period of time in a Thermomixer, and repair the sticky ends of the cDNA double strands obtained by reverse transcription under the action of the enzyme. The end repair product is purified and recovered using magnetic beads, and finally the sample is dissolved in EB Solution;

[0105] 7) Adding "A" to the end of cDNA: Prepare the "A" reaction system, react at an appropriate temperature for a certain period of time in a Thermomixer, and under the action of the enzyme, add the A base to the 3' end of the end-repaired product cDNA;

[0106] 8) Connection of cDNA adapter: Prepare the adapter connection reaction system, react at an appropriate temperature for a certain period of time in a Thermomixer, connect the adapter to the A base under the action of the enzyme, and purify and recover the product using magnetic beads.

[0107] 9) PCR reaction and product recovery: Prepare the PCR reaction system, select the appropriate PCR reaction program, and amplify the product obtained in the previous step. Purify the PCR product with magnetic beads. Dissolve the recovered product in EB solution. Attach a label, and the library preparation is now complete.

[0108] 10) Library quality detection: Agilent 2100 Bioanalyzer (Agilent DNA 1000 Reagents) was used to detect the fragment size and concentration of the library.

[0109] 11) PCR product circularization: After the PCR product is denatured into a single strand, a circularization reaction system is prepared, which is fully mixed and reacted at an appropriate temperature for a certain period of time to obtain a single-stranded circular product. After digesting the linear DNA molecules that have not been circularized, the final library is obtained.

[0110] 12) On-machine sequencing: The single-stranded circular DNA molecule is replicated through rolling circles to form a DNA nanoball (DNB) containing more than 200 copies. The obtained DNBs are added to the mesh holes on the chip using high-density DNA nanochip technology. Through the method of sequencing by synthesis, a sequencing read length of 50bp / 100bp is obtained.

[0111] 2.4 Sequencing data quality control

[0112] The raw sequencing data were filtered to obtain high-quality sequencing data (clean data). The steps were as follows: remove the adapter sequence in the reads; remove the bases containing non-AGCT at the 5' end before shearing; trim the ends of reads with low sequencing quality (sequencing quality value less than Q20); remove reads containing N at a ratio of 10%; discard small fragments less than 25bp in length after adapter removal and quality trimming.

[0113] 2.5 Alignment with reference genome

[0114] The sequencing data were aligned to the reference genome using hisat2 analysis software. The reference genome was obtained from the Ensembl database.

[0115] 2.6 Analysis of gene expression levels

[0116] The expression level of the gene was calculated by the number of sequences (clean reads) aligned to the reference genomic region. The FPKM value of each gene / transcript in the sample was calculated using Stringtie based on the alignment results of the Hisat2 software, and this value was used as the expression level of the gene / transcript in the sample.

[0117] 2.7 mRNA differential expression analysis

[0118] DESeq2 was used to compare the expression differences of mRNA between the control group and the disease group. The steps of differential analysis were as follows: first, the original read count was normalized, mainly to correct the sequencing depth; the hypothesis test probability (P-value) was calculated through a statistical model, and multiple hypothesis testing correction (BH) was performed to obtain the padj value (false discovery rate). The screening criteria for differentially expressed genes were: pvalue<0.05 and |log2foldchange|>1.

[0119] 3. Results and analysis

[0120] Compared with the control group, the biomarkers DAAM2, ECHDC3, and FOLR3 involved in the present invention were significantly upregulated in stroke patients, and the difference was statistically significant.

[0121] Example 2 Biomarker Expression

[0122] Blood samples from subjects with cardiogenic cerebral embolism (n=23, 11 females, 12 males) and subjects with a history of asymptomatic vascular disease (n=23; 11 females, 12 males) from the database were used as samples (data set GSE58294), and differential analysis of gene expression data was performed. Probes corresponding to multiple genes were removed, and then only the probe with the largest average expression level was retained for genes corresponding to multiple probes. The data set was scale-standardized. The differential analysis tool used was R-4.0.5, and the metaMA and limma packages were used for analysis. The method used for merging p values ​​in meta-analysis was the inverse normal method. The metaMA package describes the calculation of P and FDR values ​​(Calculates differential expression p-values ​​and effect sizes from data either from classical or moderated t-tests (Limma, SMVar) for study and combines these p-values ​​by the inverse normalmethod, FDR value calculation: Benjamini Hochberg threshold. By default, the False DiscoveryRate is controlled at 5%).

[0123] The screening criteria for differentially expressed genes were as follows: adj.P.Val<0.05&|logFC|>1. 208 differentially expressed genes were obtained. The expression of the biomarkers involved in the present invention in subjects with cardiogenic cerebral embolism is shown in Table 1. Figure 1-3 As shown, the biomarkers were all up-regulated in the disease groups, and the differences were statistically significant.

[0124] Table 1 Expression of biomarkers in blood samples of patients with cardiogenic cerebral embolism

[0125]

[0126]

[0127] Example 3 Diagnostic Efficacy

[0128] The receiver operating characteristic (ROC) curve can intuitively identify the diagnostic efficacy of each diagnostic index. The closer the ROC curve is to the upper left corner, the larger the area under the curve (AUC), and the higher the diagnostic value (reference The meaning and use of the area under a receiver operating characteristic (ROC) curve. [J]. Radiology, 1982). The present invention uses R language pROC to perform ROC diagnostic analysis on the above genes to screen biomarkers with diagnostic value.

[0129] result:

[0130] When AUC>0.5, the closer the AUC value is to 1, the better the diagnostic effect of the diagnostic marker. Based on the GEO data set, the present invention uses R language to draw the ROC curve of the gene involved in the present invention. The results are as follows Figure 4-6 As shown, the AUC values ​​of the genes described in the present invention are basically between 0.70 and 0.85, among which DAAM2 (AUC = 0.733), ECHDC3 (AUC = 0.829), and FOLR3 (AUC = 0.826). The diagnostic efficacy of the biomarker combination was further analyzed, as shown in FIG. Figure 7-10 , as shown in Table 2.

[0131] Table 2 Diagnostic efficacy of biomarker combinations

[0132] Biomarker Panel AUC DAAM2+ECHDC3 0.825 ECHDC3+FOLR3 0.909 DAAM2+FOLR3 0.872 DAAM2+ECHDC3+FOLR3 0.922

[0133] Compared with a single biomarker or two biomarkers, the combination of three biomarkers has better diagnostic efficacy. The above results prove that the biomarkers involved in the present invention can be used to diagnose cardiogenic cerebral embolism.

[0134] The preferred embodiments of the present application are described in detail above in conjunction with the accompanying drawings. However, the present application is not limited to the specific details in the above embodiments. Within the technical concept of the present application, the technical solution of the present application can be subjected to a variety of simple modifications, and these simple modifications all belong to the protection scope of the present application. It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner if there is no contradiction. In order to avoid unnecessary repetition, the present application will not further explain various possible combinations. In addition, the various different embodiments of the present application can also be combined arbitrarily, as long as they do not violate the idea of ​​the present application, they should also be regarded as the contents disclosed in the present application.

Claims

1. Use of a reagent for detecting the expression level of a biomarker in a sample in the preparation of a product for diagnosing stroke, characterized in that: The biomarkers include DAAM2, ECHDC3 and FOLR3.

2. The use according to claim 1, characterized in that: The reagents include reagents for detecting the expression level of biomarkers in samples through digital imaging technology, protein immunoassay technology, dye technology, nucleic acid sequencing technology, nucleic acid hybridization technology, chromatography technology, and mass spectrometry technology.

3. The use according to claim 1, characterized in that: The sample is blood.

4. The use according to claim 1, characterized in that: The reagents include primers, probes, antibodies, peptides, aptamers or compounds; wherein the primers and probes specifically bind to the genes of the biomarkers, and the antibodies, peptides, aptamers or compounds specifically bind to the proteins of the biomarkers.

5. The use according to claim 1, characterized in that: The products include nucleic acid membrane strips, preparations, chips, and test kits.

6. A system or device for diagnosing whether a subject has suffered from a stroke or predicting whether a subject has a risk of suffering from a stroke, characterized in that: The system / device comprises: an analysis unit adapted to measure the amount of a biomarker in a sample from a subject; and an evaluation unit comprising a stored reference and a data processor having implemented therein an algorithm for comparing the amount of the biomarker measured by the analysis unit with the stored reference, thereby diagnosing whether the subject suffers from a stroke or predicting whether the subject is at risk of suffering from a stroke; The biomarkers include DAAM2, ECHDC3 and FOLR3.

7. A computer-readable storage medium, characterized in that: A computer program is stored thereon, and when the computer program is executed by a processor, the system / device of claim 6 is implemented.